HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 9

Overview of DESTINY-Breast06

July 22, 2024

Joyce A. O'Shaughnessy, MD, Melinda L. Telli, MD, Aditya Bardia, MD, MPH, Ian Krop, MD, PhD, Kandace McGuire, MD

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

EP. 1: Challenges in Diagnosing HER2+ Breast Cancer

EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients

EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

Now Viewing

EP. 9: Overview of DESTINY-Breast06

EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd

EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following questions:

Briefly discuss the DESTINY-Breast06, including study design, primary endpoints, and safety:
- DESTINY-Breast06 evaluating T-DXd vs investigators choice of chemotherapy in HER2-low, HR+ mBC.
  - Based on the above data, how might this impact practice patterns in HER2-low and HER2 ultra-low disease?
  - Would the avail of first-line T-DXd for HER2-low and HER2 ultra-low patients influence your approach in the number of regimens of endocrine therapy you recommend to patients?